KRAS and squamous cell carcinoma: When developing efficacious regimens to target the activated PI3K/AKT/mTOR pathway, metastatic or recurrent squamous cell carcinomas of the cervix might be an appropriate clinical model to be tested in early-phase clinical trials because of their high prevalence of PIK3CA mutation and/or PTEN loss/mutation as previously reported [15, 32–35] and their lack of simultaneous KRAS mutation, in agreement with the hypothesis that coexisting KRAS mutation become resistant to regimens targeting the activated PI3K/AKT/mTOR pathway.